Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Estudo Clínico Contra a Diabetes Tipo 2 Intratável (CAPTAIN-T2D) (CAPTAIN-T2D)

5 de outubro de 2026 atualizado por: Sparrow Pharmaceuticals

Estudo de Fase 2 com Clofutriben e Placebo contra Diabetes Tipo 2 Intratável (CAPTAIN-T2D)

CAPTAIN-T2D will take place in two parts. Part 1 (Screening) will evaluate patients with type 2 diabetes and elevated cortisol risk factors for trial eligibility and the presence of elevated cortisol. Participants deemed eligible from Part 1 will be randomized to either clofutriben or placebo in the double-blind (participant and investigator), dose-ranging, interventional Part 2 (Treatment).

Visão geral do estudo

Status

Recrutamento

Condições

Intervenção / Tratamento

Descrição detalhada

CAPTAIN-T2D is a two-part, multicenter, randomized, double-blind, parallel group, placebo- controlled trial of the 11-hydroxysteroid dehydrogenase type 1 (HSD-1) inhibitor clofutriben. The primary objectives of this trial are to characterize the relationship of clofutriben dose to improved glycemic control, and to identify one or more doses suitable for Phase 3 evaluation, in patients with T2D and elevated cortisol.

The trial consists of two parts.

Part 1 (Screening) will last between approximately 5 to 9 weeks for most participants. The screening period duration allows for (sequentially) initial eligibility screen, dexamethasone suppression test, and further eligibility assessments.

During Part 2 (Treatment), participants will be randomized to placebo or one of four clofutriben doses. Part 2 will last 24 weeks with a follow-up phone call 4 weeks after the last dose of trial medication.

Tipo de estudo

Intervencional

Inscrição (Estimado)

1500

Estágio

  • Fase 2

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • Arizona
      • Chandler, Arizona, Estados Unidos, 85225
        • Recrutamento
        • Arizona Clinical Trials - Pecos
        • Contato:
      • Tucson, Arizona, Estados Unidos, 85711
    • California
      • Fountain Valley, California, Estados Unidos, 92708
        • Recrutamento
        • Ark Clinical Research - Fountain Valley
        • Contato:
      • Huntington Park, California, Estados Unidos, 90255
        • Recrutamento
        • Velocity Clinical Research, Huntington Park
        • Contato:
      • La Mesa, California, Estados Unidos, 91942
      • Long Beach, California, Estados Unidos, 90815
      • Los Angeles, California, Estados Unidos, 90057
      • Los Angeles, California, Estados Unidos, 90015
        • Recrutamento
        • Los Angeles Institute for Metabolic Research
        • Contato:
      • Northridge, California, Estados Unidos, 98433
        • Recrutamento
        • Amicis Research Center- Nordhoff
        • Contato:
      • San Diego, California, Estados Unidos, 92120
    • Florida
      • Edgewater, Florida, Estados Unidos, 32132
        • Recrutamento
        • Velocity Clinical Research, New Smyrna Beach
        • Contato:
      • Fort Lauderdale, Florida, Estados Unidos, 33312
        • Recrutamento
        • The Center for Diabetes and Endocrine Care
        • Contato:
      • Miami, Florida, Estados Unidos, 33173
      • New Port Richey, Florida, Estados Unidos, 34652
      • Port Charlotte, Florida, Estados Unidos, 33952
        • Recrutamento
        • Innovative Research Institute
        • Contato:
      • Port Orange, Florida, Estados Unidos, 32127
      • Winter Park, Florida, Estados Unidos, 32789
    • Georgia
      • Atlanta, Georgia, Estados Unidos, 30303
        • Recrutamento
        • Emory University School of Medicine
        • Contato:
      • Columbus, Georgia, Estados Unidos, 31904
    • Idaho
      • Boise, Idaho, Estados Unidos, 83709
    • Illinois
      • Chicago, Illinois, Estados Unidos, 60607
        • Recrutamento
        • Chicago Clinical Research Institute
        • Contato:
          • Manognya Clinical Research Manager
          • Número de telefone: 303 3127913241
          • E-mail: manognya@ccrii.us
    • Iowa
      • West Des Moines, Iowa, Estados Unidos, 50226
        • Recrutamento
        • Iowa Diabetes and Endocrinology Research Center
        • Contato:
    • Kansas
      • Wichita, Kansas, Estados Unidos, 67226
        • Recrutamento
        • Alliance for Multispecialty Research - Wichita East
        • Contato:
    • Kentucky
      • Edgewood, Kentucky, Estados Unidos, 41017
    • Louisiana
      • Lafayette, Louisiana, Estados Unidos, 70508
      • Metairie, Louisiana, Estados Unidos, 70006
        • Recrutamento
        • NOLA Care Clinical Research
        • Contato:
      • New Orleans, Louisiana, Estados Unidos, 70112
        • Recrutamento
        • Tulane University School of Medicine
        • Contato:
    • Maryland
      • Rockville, Maryland, Estados Unidos, 20854
    • Massachusetts
      • Springfield, Massachusetts, Estados Unidos, 011030
    • Michigan
      • Troy, Michigan, Estados Unidos, 48085
        • Recrutamento
        • Oakland Medical Research Center
        • Contato:
          • Juliejo (Julie) Clinical Research Manager
          • Número de telefone: 248-687-7412
          • E-mail: juliejolafave@msn.com
    • Nebraska
      • Lincoln, Nebraska, Estados Unidos, 68510
      • Omaha, Nebraska, Estados Unidos, 68134
    • Nevada
      • Las Vegas, Nevada, Estados Unidos, 89148
      • Las Vegas, Nevada, Estados Unidos, 89108
    • New York
      • Albany, New York, Estados Unidos, 12203
        • Recrutamento
        • Albany Medical College
        • Contato:
    • North Carolina
      • Chapel Hill, North Carolina, Estados Unidos, 27514
        • Recrutamento
        • University of North Carolina at Chapel Hill
        • Contato:
      • Greenville, North Carolina, Estados Unidos, 27834
      • Morehead City, North Carolina, Estados Unidos, 28557
      • Wilmington, North Carolina, Estados Unidos, 28401
        • Recrutamento
        • PMG Research of Wilmington, LLC
        • Contato:
    • Ohio
      • Cincinnati, Ohio, Estados Unidos, 45219
        • Recrutamento
        • Velocity Clinical Research, Cincinnati, Mt. Auburn
        • Contato:
      • Cincinnati, Ohio, Estados Unidos, 45242
        • Recrutamento
        • Velocity Clinical Research - Cincinnati, Blue Ash
        • Contato:
      • Columbus, Ohio, Estados Unidos, 43201
        • Recrutamento
        • Endocrinology Associates, Inc
        • Contato:
      • Columbus, Ohio, Estados Unidos, 43215
        • Recrutamento
        • Remington Davis, Inc
        • Contato:
    • Oregon
      • Eugene, Oregon, Estados Unidos, 97404
        • Recrutamento
        • Willamette Valley Clinical Studies
        • Contato:
          • Patricia Manager
          • Número de telefone: 541-461-0132
          • E-mail: drpatb@aol.com
    • Pennsylvania
      • West Chester, Pennsylvania, Estados Unidos, 19380
    • South Carolina
      • Anderson, South Carolina, Estados Unidos, 29621
      • Mt. Pleasant, South Carolina, Estados Unidos, 29464
    • Texas
      • Austin, Texas, Estados Unidos, 78759
      • Dallas, Texas, Estados Unidos, 75230
      • Houston, Texas, Estados Unidos, 77040
      • Lampasas, Texas, Estados Unidos, 76550
        • Recrutamento
        • Radiance Clinical Research
        • Contato:
      • Lewisville, Texas, Estados Unidos, 75057
        • Recrutamento
        • Alliance Clinical - Lewisville (Epic Clinical Research)
        • Contato:
      • Mission, Texas, Estados Unidos, 78572
        • Recrutamento
        • Texas Valley Clinical Research - Mission, TX
        • Contato:
      • Round Rock, Texas, Estados Unidos, 78681
        • Recrutamento
        • Texas Diabetes & Endocrinology, P.A. - Round Rock
        • Contato:
      • San Antonio, Texas, Estados Unidos, 78229
        • Recrutamento
        • Diabetes & Glandular Disease Clinic, P.A.
        • Contato:
      • San Antonio, Texas, Estados Unidos, 78251
        • Recrutamento
        • Texas Valley Clinical Research - San Antonio TX
        • Contato:
      • Seabrook, Texas, Estados Unidos, 77586
      • Weslaco, Texas, Estados Unidos, 78596
        • Recrutamento
        • Texas Valley Clinical Research, LLC
        • Contato:
    • Utah
      • West Jordan, Utah, Estados Unidos, 84088
        • Recrutamento
        • Velocity Clinical Research, Salt Lake City
        • Contato:
    • Virginia
      • Suffolk, Virginia, Estados Unidos, 23435
      • Vienna, Virginia, Estados Unidos, 22182

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • From Screening 1

    • Age at least 18 years.

    • HbA1c ≥7.5% documented within 3 months prior to Screening 1. (The historical HbA1c value must have been obtained after at least 2 months on the current [as of Screening 1] regimen).

    • Treatment with stable and adequate doses of ≥2 injectable or oral ADMs. (An ADM will be deemed stable if the dose has been the same for at least 3 months prior to Screening 1 and without change between Screening 1 and Day 1) (An ADM dose will be deemed adequate if it is at or above the maximal labelled dose, or a sub-maximal, but not starting, dose if limited by tolerability (confer with MM if less than half-maximal dose).

    • Adequate total daily insulin is defined as at least 0.3 units/kg/day. Insulin dose will be deemed stable with adjustments of up to 20% total daily dose during the 3 months prior to Screening 1 or between Screening 1 and Day 1.

    • Use of insulin pumps or insulin brand changes (e.g., due to insurance change or shortage) are to be discussed with the MM.

    • At least one of the following

      • ≥3 stable and adequate ADMs;
      • diabetes complication (retinopathy, nephropathy, neuropathy, atherosclerotic heart disease);
      • hypertension requiring ≥2 adequately dosed AHMs;
      • adequately dosed basal or basal plus prandial insulin in addition to at least 1 other ADM; and
      • adequately dosed incretin agonist (a single or combination agent counts as one ADM) in addition to at least 1 other ADM;
      • evidence or history of osteoporosis or non-traumatic fracture (e.g., vertebral body compression);
      • or established diagnosis of a neoplastic (non-malignant) source of hypercortisolism and have failed, are ineligible for, or declined surgery.

At DST • Post-DST cortisol level >1.8 µg/dL and serum dexamethasone ≥140 ng/dL. Patients with an established diagnosis of neoplastic hypercortisolism do not require a DST.

At Screening 2

  • HbA1c ≥7.5% at Screening 2. At Day 1
  • No change in, or initiation of, medications for hypertension within 1 month prior to Day 1.

Exclusion Criteria:

  • New-onset diabetes (onset <1 year in the past).

  • Unwillingness to maintain with current glucose-lowering regimen during the trial.

  • Unwillingness to adjust, add, replace, or discontinue current or other glucose-lowering medications during the trial as directed by the investigator.

  • Unwillingness to comply with CGM or other trial procedures.

  • Investigator considers the patient will otherwise be unwilling or unable to complete the trial.

  • Night-shift worker or otherwise habitually awake from 23:00 to 07:00 h.

  • Evidence for significant hypoglycemia while on their current diabetic treatment regimen(This includes episodes of symptomatic Level 3 hypoglycemia requiring external assistance for recovery, or CGM-documented prolonged [>15 min] or repeated episodes of either Level 2 hypoglycemia leading to >1%, or Level 1 hypoglycemia leading to >4%, in "time below range" within 3 months prior to Screening 1 or between Screening 1 and Day 1).

  • Any of the following in medical history:

    • Type 1 diabetes mellitus (T1D), latent autoimmune diabetes in adults (LADA), or familial forms of maturity-onset diabetes of the young (MODY);
    • A hemoglobinopathy or other condition which may interfere with measurement of HbA1c (e.g., sickle cell disease HbSS or other variants HbEE thalassemia, hemolytic anemia, recent blood transfusion);
    • Hypersensitivity or severe reaction to dexamethasone;
    • Pheochromocytoma, or suspicion thereof;
    • Anorexia, or other eating disorder;
    • Glucocorticoid resistance;
    • Multiple sclerosis;
    • Significant hepatic impairment (e.g., Child-Pugh Class B or C);
    • Idiopathic thrombocytopenic purpura;
    • Untreated or inadequately controlled moderate-to-severe sleep apnea (apnea-hypopnea index ≥15). (Patients whose condition has been well controlled with Continuous Positive Airway Pressure (CPAP) use for at least 3 months prior to Screening 1 are not excluded. Patients with a STOP-BANG score 5-8 should be referred for a sleep study outside the trial and may rescreen if found not to have moderate-to-severe sleep apnea);
    • Current alcohol consumption >14 units/week or >4 units in a single day for males, or >7 units/week or >3 units in a single day for females. (Patients with a CAGE score 2-4 should be evaluated further outside the trial and may be rescreened if found not to have an alcohol [or other substance] use disorder);
    • Untreated or inadequately controlled major depressive disorder, generalized anxiety disorder, bipolar disorder, post-traumatic stress disorder, or schizophrenia.(Patients whose condition has been well controlled with stable medical therapy, or has been asymptomatic, for at least 3 months prior to Screening 1 are not excluded); or
    • Any other medical condition (including malignancy) that is likely to interfere with trial assessments or the patient's ability to complete the trial.
    • Any of the following in medication history:
    • Any of the excluded medications listed in Section 6.9;
    • Any investigational drug within 4 weeks or within less than five times the drug's half-life, whichever is longer, prior to Screening 1 or between Screening 1 and Day 1;
    • Woman of childbearing potential (WOCBP) not willing to adhere to highly effective contraception or strict abstinence for the duration of the trial and for 90 days post completion/discontinuation; and
    • Pregnancy (including a positive urine test) or current breast feeding.

From Screening 2

• Prior probability of undiagnosed endogenous Cushing syndrome based on either of:

  • wo morning serum cortisol values after dexamethasone suppression >5.0 mcg/dL together with plasma dexamethasone >140 ng/mL; or
  • a morning serum cortisol value after dexamethasone suppression >1.8 mcg/dL, together with plasma dexamethasone >140 ng/mL and any one of the following that is not attributable to an etiology other than endogenous Cushing's syndrome:
  • supraclavicular/dorsocervical fat accumulation;
  • irounding of the face (especially compared with prior photos);
  • skin changes (violaceous striae, skin thinning, or excessive bruising);
  • proximal muscle weakness on exam; or
  • history of deep vein thrombosis/pulmonary embolism.
  • Plans for, or medically unable to forego, treatment for endogenous Cushing syndrome or ACS within the next 8 months. (For clarity, patients with EnCS or ACS, not having such treatment plans, and medically able to forego treatment for 8 months may enroll if otherwise eligible).
  • Severe, poorly controlled hypertension (mean systolic BP >160 mmHg or mean diastolic BP >100 mmHg) at Screening 2 or between Screening 2 and Day 1, including by at-home monitoring. (Such patients will be eligible to rescreen for Part 2 when they restore BP <160/100 mmHg for 1 month on a new stable medication regimen).
  • Positive urine screen for recreational drugs (except tetrahydrocannabinol (THC)).
  • Glomerular filtration rate (GFR) (determined using Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI]) <45 mL/min/1.73 m².
  • Poorly controlled hyperthyroidism/hypothyroidism (confirmed by TSH or Free thyroxine [fT4]).
  • Liver enzymes >3 × upper limit of normal (ULN) (alanine aminotransferase (ALT) or aspartate aminotransferase (AST) or bilirubin >1.5 × ULN.(excepting benign conditions such as Gilbert's)
  • Known hypersensitivity to clofutriben or to any of the product

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Outro
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Quadruplicar

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Dose 1

clofutriben .2 mg oral tablet daily

HSD-1 inhibitor

Outros nomes:
  • SPI-62
  • ASP3662
Experimental: Dose 2

clofutriben 2mg oral tablet daily

HSD-1 inhibitor

Outros nomes:
  • SPI-62
  • ASP3662
Experimental: Dose 3

clofutriben 6mg oral tablet daily

HSD-1 inhibitor

Outros nomes:
  • SPI-62
  • ASP3662
Experimental: Dose 4

clofutriben 12 mg oral tablet daily

HSD-1 inhibitor

Outros nomes:
  • SPI-62
  • ASP3662
Comparador de Placebo: placebo

placebo control oral tablet daily

Placebo

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Percentage of patients with both morning serum cortisol >1.8 mg/dL and morning plasma dexamethasone >=140 ng/dL (single composite endpoint) after a single dexamethasone 1 mg dose taken the prior night.
Prazo: 8-10 hours after the dexamethasone 1 mg dose.

To assess prevalence in the trial population of morning cortisol non-suppression by a single dexamethasone 1 mg dose.

8-10 hours after the dexamethasone 1 mg dose.
Glycated hemoglobin A1c (%) change from baseline to Week 24 by treatment.
Prazo: 24 weeks.

To assess glycated hemoglobin A1c (%) changes, compared to placebo, in patients who receive each of 4 daily clofutriben doses for 24 weeks.

24 weeks.

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Fasting plasma glucose (mmol/L) change from baseline to Week 24 by treatment.
Prazo: 24 weeks

To assess glucose (mmol/L) changes, compared to placebo, in patients who receive each of 4 daily clofutriben doses for 24 weeks.

24 weeks

Outras medidas de resultado

Medida de resultado
Descrição da medida
Prazo
To evaluate the safety of clofutriben in participants with T2D and EC.
Prazo: From enrollment until end of trial 9 month

Frequency of TEAEs (treatment-emergent adverse even) by clofutriben dose

From enrollment until end of trial 9 month

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

29 de novembro de 2025

Conclusão Primária (Estimado)

31 de dezembro de 2027

Conclusão do estudo (Estimado)

30 de junho de 2028

Datas de inscrição no estudo

Enviado pela primeira vez

30 de novembro de 2025

Enviado pela primeira vez que atendeu aos critérios de CQ

18 de dezembro de 2025

Primeira postagem (Real)

22 de dezembro de 2025

Atualizações de registro de estudo

Última Atualização Postada (Real)

6 de outubro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

5 de outubro de 2026

Última verificação

1 de outubro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • SPI-62-CL-2006

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .